TBPK 2018 – Presentations

Tuesday, 23 October 2018

 Session 1: Pharmacokinetics and pharmacodynamics of new TB drugs
Chairs: Rob Aarnoutse & Jan-Willem Alfenaar
 New developments in pediatric TB treatment
Anneke Hesseling
Desmond Tutu Tuberculosis Centre, South Africa
(Not yet available)
 Abstract-driven presentations
 CPK/PD Support for a Phase 1 Study of TBA-7371
Jerry Nedelman, PhD
#1
 Bedaquiline appears to antagonize its own main metabolite’s QTcF interval
prolonging effect
Lénaïg Tanneau, PhD
#2
 Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline
An Vermeulen, PhD
#3
 Preclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid
Suresh Mallikaarjun, PHD, FCP
#4
 Session 2: Pharmacokinetics and pharmacodynamics of approved TB drugs
Chairs: Geraint Davies & Helen McIlleron
 Abstract-driven presentations
 Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB
Andrew McCallum, MBChB
#5
 Rifampicin, isoniazid and pyrazinamide exposures in children with DS-TB on
WHO-recommended FDCs in the SHINE trial
Helen McIlleron, MBChB, PhD
(Not yet available)
#6
 Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention
Anthony Podany, PharmD
#7
 Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers
Charles Peloquin, PharmD
#8
 Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis
Sean Wasserman, MBChB, MMed
#9
 Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients
Charles Peloquin, PharmD
#10
 Session 3: Population pharmacokinetics and pharmacokinetic-pharmacodynamic modeling
 Chairs: Jerry Nedelman & Eric Nuermberger
 Treatment of Multi-Drug Resistant TB
Bob Horsburgh
 Abstract-driven presentations
 High peak rifampicin concentrations accelerate the slow phase of bacterial elimination in tuberculosis patients
Antal Martinecz
#11
 The Clinical value of Model-based Therapeutic Drug Monitoring in Tuberculosis Treatment – Optimized Target for Rifampicin
Ulrika Simonsson
(Not yet available)
#12
 Model-based meta-analysis of rifampicin exposure and mortality in phase II
tuberculosis meningitis trials
Elin M Svensson
#13
 Session 4: Drug development and optimization: approaches and tools
Chairs: Charles Peloquin & Kelly Dooley
 Abstract-driven presentations
 Clinical Validation of Intracellular Pharmacodynamic (PDi) based modelling for the prediction of Fluoroquinolone activity against TB
Ghaith Aljayyoussi, PhD
#15
 Pharmacodynamic Correlates of Linezolid Activity and Toxicity in a Mouse TB Model
Kristina Bigelow, MS
#17
 Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis
Elizabeth Tucker, MD
#18
 Protein binding of rifampicin is not saturated when using high-dose rifampicin
Carlijn Litjens, MSc
#19
 Using Mycobacterium tuberculosis single nucleotide polymorphisms to predict fluoroquinolone treatment response
Timothy Rodwell, MD PhD MPH
#20